Early data shows mRNA-4359 may benefit patients with advanced solid cancers
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
http://dlvr.it/TDHDh8
http://dlvr.it/TDHDh8
Comments
Post a Comment